Prestige Consumer Healthcare (NYSE:PBH) Releases FY 2027 Earnings Guidance

Prestige Consumer Healthcare (NYSE:PBH) issued an update on its FY 2027 earnings guidance on Thursday morning. The company provided EPS guidance of 4.550-4.650 for the period, compared to the consensus estimate of 4.580. The company issued revenue guidance of $1.3 billion-$1.3 billion, compared to the consensus revenue estimate of $1.2 billion.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. Oppenheimer cut shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. Weiss Ratings cut Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, June 25th. Canaccord Genuity Group lowered their price target on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a research note on Friday, May 15th. Finally, Zacks Research downgraded shares of Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a report on Monday, May 18th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $70.75.

Prestige Consumer Healthcare Price Performance

Shares of Prestige Consumer Healthcare stock traded up $0.38 during mid-day trading on Friday, reaching $54.81. 98,734 shares of the stock were exchanged, compared to its average volume of 563,011. Prestige Consumer Healthcare has a fifty-two week low of $42.62 and a fifty-two week high of $71.07. The company has a market cap of $2.60 billion, a price-to-earnings ratio of 14.02, a price-to-earnings-growth ratio of 1.70 and a beta of 0.34. The firm has a 50-day simple moving average of $48.67 and a 200 day simple moving average of $56.07. The company has a current ratio of 3.57, a quick ratio of 2.25 and a debt-to-equity ratio of 0.54.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, August 6th. The company reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.89 by $0.09. The company had revenue of $265.71 million during the quarter, compared to analysts’ expectations of $250.34 million. Prestige Consumer Healthcare had a net margin of 17.48% and a return on equity of 11.54%. Prestige Consumer Healthcare’s quarterly revenue was up 6.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.90 earnings per share. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. On average, sell-side analysts predict that Prestige Consumer Healthcare will post 4.45 EPS for the current fiscal year.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Several institutional investors have recently made changes to their positions in the stock. AQR Capital Management LLC lifted its position in Prestige Consumer Healthcare by 11.9% during the first quarter. AQR Capital Management LLC now owns 30,056 shares of the company’s stock worth $2,558,000 after purchasing an additional 3,200 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Prestige Consumer Healthcare by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,490 shares of the company’s stock worth $2,535,000 after acquiring an additional 1,289 shares in the last quarter. Goldman Sachs Group Inc. raised its position in Prestige Consumer Healthcare by 28.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company’s stock valued at $46,997,000 after buying an additional 120,965 shares during the last quarter. Jane Street Group LLC increased its holdings in Prestige Consumer Healthcare by 204.0% during the 1st quarter. Jane Street Group LLC now owns 104,802 shares of the company’s stock worth $9,010,000 after acquiring an additional 70,330 shares during the period. Finally, Geneos Wealth Management Inc. increased its position in shares of Prestige Consumer Healthcare by 92.8% in the first quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock valued at $48,000 after acquiring an additional 269 shares during the period. 99.95% of the stock is currently owned by institutional investors.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).